Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment

• Published in: Life (Basel, Switzerland) Vol. 13; no. 3; p. 828
• Main Authors: Diaz, Michael Joseph, Mark, Isabella, Rodriguez, Daphnee, Gelman, Beata, Tran, Jasmine Thuy, Kleinberg, Giona, Levin, Anna, Beneke, Alice, Root, Kevin Thomas, Tran, Andrew Xuan Vinh, Lucke-Wold, Brandon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: Biomarkers; Brain; Brain cancer; Brain research; Cancer; Cancer therapies; Care and treatment; cerebral metastases; Chemotherapy; Clinical trials; Complications and side effects; Diagnosis; early detection; Effectiveness; FDA approval; Immunotherapy; Insulin-like growth factors; Literature reviews; MBM; Medical prognosis; Melanoma; Metastases; Metastasis; Mortality; Oncology, Experimental; Patients; Radiation therapy; Radiosurgery; Skin cancer; Systematic Review; United States; MBM; melanoma; early detection; cerebral metastases; systematic review
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life13030828

Melanoma continues to represent the most serious skin cancer worldwide. However, few attempts have been made to connect the body of research on advanced melanoma. In the present review, we report on strides made in the diagnosis and treatment of intracranial metastatic melanoma. Relevant Cochrane reviews and randomized-controlled trials published by November 2022 were systematically retrieved from the Cochrane Library, EMBASE, and PubMed databases (N = 27). Search and screening methods adhered to the 2020 revision of the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Although the research surrounding the earlier detection of melanoma brain metastasis is scarce, several studies have highlighted specific markers associated with MBM. Such factors include elevated BRAFV600 mutant ctDNA, high LDH concentration, and high IGF-1R. The approach to treating MBM is moving away from surgery and toward nonsurgical management, namely, a combination of stereotactic radiosurgery (SRS) and immunotherapeutic agents. There is an abundance of emerging research seeking to identify and improve both novel and established treatment options and diagnostic approaches for MBM, however, more research is still needed to maximize the clinical efficacy, especially for new immunotherapeutics. Early detection is optimal for the efficacy of treatment and MBM prognosis. Current treatment utilizes chemotherapies and targeted therapies. Emerging approaches emphasize biomarkers and joint treatments. Further exploration toward preliminary identification, the timing of therapies, and methods to ameliorate adverse treatment effects are needed to advance MBM patient care.